![How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer](https://dailynews.ascopubs.org/do/10.1200/ADN.21.200667/full/dn21_cc_lam_table-1626869738013.png)
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
![Diagnostics | Free Full-Text | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib Diagnostics | Free Full-Text | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib](https://pub.mdpi-res.com/diagnostics/diagnostics-11-02170/article_deploy/html/images/diagnostics-11-02170-g001.png?1637675050)
Diagnostics | Free Full-Text | Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
![Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer | Semantic Scholar Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/77f99ea213d341b16f406ceb1a9d48d6c4bb8b13/4-Figure2-1.png)
Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer | Semantic Scholar
![Frontiers | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients Frontiers | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients](https://www.frontiersin.org/files/Articles/534736/fonc-10-01299-HTML/image_m/fonc-10-01299-g001.jpg)
Frontiers | Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
![Kaplan-Meier analyses of survival in patients treated with alectinib... | Download Scientific Diagram Kaplan-Meier analyses of survival in patients treated with alectinib... | Download Scientific Diagram](https://www.researchgate.net/publication/357421571/figure/fig1/AS:1106690451750912@1640866973546/Kaplan-Meier-analyses-of-survival-in-patients-treated-with-alectinib-and-crizotinib-A.png)
Kaplan-Meier analyses of survival in patients treated with alectinib... | Download Scientific Diagram
![Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753420397969-gr2.jpg)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
![Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer - ScienceDirect Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S205970292200148X-gr1.jpg)
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer - ScienceDirect
![Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/05d4bdcd-5294-43b6-893a-92a9bd1326c7/figs1.jpg)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
Stephen V Liu, MD on Twitter: "#ESMOAsia22 Survival is favoring alectinib for #ALK NSCLC over crizotinib, but not yet significant. Medians not reached and OS HR 0.60 overall with OS HR 0.40
![Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram](https://www.researchgate.net/publication/287497086/figure/fig2/AS:614128121024512@1523430962501/Progression-free-survival-by-IRC-Shown-is-the-Kaplan-Meier-curve-for-estimated-PFS-among.png)
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
![Cancers | Free Full-Text | Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials Cancers | Free Full-Text | Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials](https://www.mdpi.com/cancers/cancers-12-00526/article_deploy/html/images/cancers-12-00526-g004.png)
Cancers | Free Full-Text | Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program | Oncotarget
![Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/a2594401-024e-4f1d-bd08-a5e72e26e264/gr2_lrg.jpg)
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
![Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan - Masuda - 2019 - Cancer Science - Wiley Online Library Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan - Masuda - 2019 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/b120fc83-0a14-4d35-8d6b-8b36ab7192c0/cas13977-fig-0003-m.jpg)
Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan - Masuda - 2019 - Cancer Science - Wiley Online Library
![Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer | SpringerLink Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40801-020-00207-6/MediaObjects/40801_2020_207_Fig3_HTML.png)
Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer | SpringerLink
![Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - ScienceDirect Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0169500219306968-gr1.jpg)
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - ScienceDirect
![Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/42ecc55a-1e79-448a-95bd-531462a43072/gr2.jpg)